SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-22-012120
Filing Date
2022-05-12
Accepted
2022-05-12 16:02:37
Documents
14
Period of Report
2022-05-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K navb20220512_8k.htm   iXBRL 8-K 30604
2 EXHIBIT 99.1 ex_374934.htm EX-99.1 80185
  Complete submission text file 0001437749-22-012120.txt   272406

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA navb-20220512.xsd EX-101.SCH 4237
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20220512_def.xml EX-101.DEF 13857
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20220512_lab.xml EX-101.LAB 18178
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20220512_pre.xml EX-101.PRE 13886
8 EXTRACTED XBRL INSTANCE DOCUMENT navb20220512_8k_htm.xml XML 4789
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35076 | Film No.: 22917665
SIC: 2835 In Vitro & In Vivo Diagnostic Substances